Apolipoprotein A-I glycation by Glucose and Reactive Aldehydes Alters Phospholipid Affinity but Not Cholesterol Export from Lipid-Laden Macrophages

PLoS ONE

Volumn 8, Issue 5, 2013, Pages

  Brown, Bronwyn E ^a,c   Nobecourt, Estelle ^a   Zeng, Jingmin ^a   Jenkins, Alicia J ^b   Rye, Kerry Anne ^a,b,c   Davies, Michael J ^a,c  

^a HEART RESEARCH INSTITUTE   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

^c University of Sydney   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ABC TRANSPORTER A1; ABC TRANSPORTER G1; ADVANCED GLYCATION END PRODUCT; ALDEHYDE; AMINOGUANIDINE; APOLIPOPROTEIN A1; ARGININE; CHOLESTEROL; DIGLYCOALDEHYDE; GLUCOSE; HIGH DENSITY LIPOPROTEIN; LIPID; LYSINE; METHYLGLYOXAL; PHOSPHOLIPID; TRYPTOPHAN;

ADULT; ANIMAL CELL; ARTICLE; BINDING AFFINITY; CELL VACUOLE; CHOLESTEROL TRANSPORT; CLINICAL ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN CELL; INSULIN DEPENDENT DIABETES MELLITUS; MACROPHAGE; MALE; MOUSE; NONHUMAN; PROTEIN CROSS LINKING; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN GLYCOSYLATION; PROTEIN MODIFICATION; PROTEIN STRUCTURE;

ADULT; ALDEHYDES; ANIMALS; APOLIPOPROTEIN A-I; ATP-BINDING CASSETTE TRANSPORTERS; BIOLOGICAL TRANSPORT; CASE-CONTROL STUDIES; CELL LINE; CHOLESTEROL; DIABETES MELLITUS, TYPE 1; FEMALE; GLUCOSE; GLYCOSYLATION; HUMANS; LIPID METABOLISM; LIPOPROTEINS, HDL; MACROPHAGES; MALE; MICE; PHOSPHOLIPIDS; YOUNG ADULT;

MURINAE;

EID: 84878611335     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0065430     Document Type: Article

References (42)

1. World Health Organisation (2002) Diabetes Mellitus (Fact sheet No 138). Geneva: WHO.
2. Jenkins AJ, Lyons TJ, Zheng D, Otvos JD, Lackland DT, et al. (2003) Lipoproteins in the DCCT/EDIC cohort: associations with diabetic nephropathy. Kidney Int 64: 817-828.
3. Diabetes Control and Complications Trial (2005) Intensive diabetes treatment and cardiovascular disease in patients with Type 1 diabetes. New Engl J Med 353: 2643-2655.
4. Giacco F, Brownlee M, (2010) Oxidative stress and diabetic complications. Circ Res 107: 1058-1070.
5. Thorpe SR, Baynes JW, (2003) Maillard reaction products in tissue proteins: new products and new perspectives. Amino Acids 25: 275-281.
6. Thornalley PJ, (1996) Pharmacology of methylglyoxal: formation, modification of proteins and nucleic acids, and enzymatic detoxification-a role in pathogenesis and antiproliferative chemotherapy. Gen Pharmacol 27: 565-573.
7. Lapolla A, Flamini R, Dalla Vedova A, Senesi A, Reitano R, et al. (2003) Glyoxal and methylglyoxal levels in diabetic patients: quantitative determination by a new GC/MS method. Clin Chem Lab Med 41: 1166-1173.
8. Imanaga Y, Sakata N, Takebayashi S, Matsunaga A, Sasaki J, et al. (2000) In vivo and in vitro evidence for the glycoxidation of low density lipoprotein in human atherosclerotic plaques. Atherosclerosis 150: 343-355.
9. Brown BE, Dean RT, Davies MJ, (2005) Glycation of low-density lipoproteins by methylglyoxal and glycolaldehyde gives rise to the in vitro formation of lipid-laden foam cells. Diabetologia 48: 361-369.
10. Brown BE, Rashid I, van Reyk DM, Davies MJ, (2007) Glycation of low-density lipoprotein results in the time-dependent accumulation of cholesteryl esters and apolipoprotein B-100 protein in primary human monocyte-derived macrophages. FEBS J 74: 1530-1541.
11. Yancey PG, Bortnick AE, Kellner-Weibel G, de la llera-Moya M, Phillips MC, et al. (2003) Importance of different pathways of cellular cholesterol efflux. Arterioscler Thromb Vasc Biol 23: 712-719.
12. Wang M, Briggs MR, (2002) HDL: the metabolism, function and therapeutic importance. Chem Rev 104: 119-138.
13. Wang N, Lan D, Chen W, Matsuura F, Tall AR, (2004) ATP-binding cassette transporters G1 and G4 mediate cellular efflux to high-density lipoproteins. Proc Natl Acad Sci USA 101: 9774-9779.
14. Nobecourt E, Tabet F, Lambert G, Puranik R, Bao S, et al. (2010) Nonenzymatic glycation impairs the antiinflammatory properties of apolipoprotein A-I. Arterioscler Thromb Vasc Biol 30: 766-772.
15. Nobecourt E, Davies MJ, Brown BE, Curtiss LK, Bonnet DJ, et al. (2007) The impact of glycation on apolipoprotein A-I structure and its ability to activate lecithin:cholesterol acyltransferase. Diabetologia 50: 643-653.
16. Jang W, Jeoung NH, Cho KH, (2011) Modified apolipoprotein (apo) A-I by artificial sweetener causes severe premature cellular senescence and atherosclerosis with impairment of functional and structural properties of apoA-I in lipid-free and lipid-bound state. Mol Cells 31: 461-470.
17. Park KH, Jang W, Kim KY, Kim JR, Cho KH, (2010) Fructated apolipoprotein A-I showed severe structural modification and loss of beneficial functions in lipid-free and lipid-bound state with acceleration of atherosclerosis and senescence. Biochem Biophys Res Commun 392: 295-300.
18. Passarelli M, Tang C, McDonald TO, O'Brien KD, Gerrity RG, et al. (2005) Advanced glycation end product precurors impair ABCA1-dependent cholesterol removal from cells. Diabetes 54: 2198-2205.
19. Iborra RT, Machado-Lima A, Castilho G, Nunes VS, Abdalla DS, et al. (2011) Advanced glycation in macrophages induces intracellular accumulation of 7-ketocholesterol and total sterols by decreasing the expression of ABCA-1 and ABCG-1. Lipids Health Dis 10: 172.
20. Duell PB, Oram JF, Bierman EL, (1991) Nonenzymatic glycosylation of HDL and impaired HDL-receptor-mediated cholesterol efflux. Diabetes 40: 377-384.
21. Rashduni DL, Rifici VA, Schneider SH, Khachadurian AK, (1999) Glycation of high-density lipoprotein does not increase its susceptibility to oxidation or diminish its cholesterol efflux capacity. Metab Clin Exp 48: 139-143.
22. Hoang A, Murphy AJ, Coughlan MT, Thomas MC, Forbes JM, et al. (2007) Advanced glycation of apolipoprotein A-I impairs its anti-atherogenic properties. Diabetologia 50: 1770-1779.
23. Matsuki K, Tamasawa N, Yamashita M, Tanabe J, Murakami H, et al. (2009) Metformin restores impaired HDL-mediated cholesterol efflux due to glycation. Atherosclerosis 206: 434-438.
24. Rye K-A, Garrety KH, Barter PJ, (1993) Preparation and characterisation of spheroidal, reconstituted high-denisty lipoproteins with apolipoprotein A-I only or with apolipoprotein A-I and A-II. Biochim Biophys Acta 1167: 316-325.
25. Knott HM, Brown BE, Davies MJ, Dean RT, (2003) Glycation and glycoxidation of low-density lipoproteins by glucose and low molecular weight aldehydes: formation of modified and oxidised proteins. Eur J Biochem 270: 3572-3582.
26. Zeng J, Davies MJ, (2005) Evidence for the formation of adducts and S-(carboxymethyl)cysteine on reaction of a-dicarbonyl compounds with thiol groups on amino acids, peptides, and proteins. Chem Res Toxicol 18: 1232-1241.
27. Segall ML, Dhanasekaran P, Baldwin F, Anantharamaiah GM, Weisgraber KH, et al. (2002) Influence of apoE domain structure and polymorphism on the kinetics of phospholipid vesicle solubilization. J Lipid Res 43: 1688-1700.
28. Pownall HJ, Massey JB, Kusserow SK, Gotto AM Jr, (1978) Kinetics of lipid-protein interactions: interaction of apolipoprotein A-I from human plasma high density lipoproteins with phosphatidylcholines. Biochemistry 17: 1183-1188.
29. Sakr SW, Williams DL, Stoudt GW, Phillips MC, Rothblat GH, (1999) Induction of cellular cholesterol efflux to lipid-free apolipoprotein A-I by cAMP. Biochim Biophys Acta 1438: 85-98.
30. Passarelli M, Shimabukuro AFM, Catanozi S, Nakandakare ER, Rocha JC, et al. (2000) Diminished rate of mouse peritoneal macrophage cholesterol efflux is not related to the degree of HDL glycation in diabetes mellitus. Clin Chim Acta 301: 119-134.
31. Jenkins AJ, Best JD, Klein RL, Lyons TJ, (2004) Lipoproteins, glycoxidation and diabetic angiopathy. Diabetes Metab Res Rev 20: 349-368.
32. Shao B, Pennathur S, Pagani I, Oda MN, Witztum JL, et al. (2010) Modifying apolipoprotein A-I by malondialdehyde, but not by an array of other reactive carbonyls, blocks cholesterol efflux by the ABCA1 pathway. J Biol Chem 285: 18473-18484.
33. Lo TW, Westwood ME, McLellan AC, Selwood T, Thornalley PJ, (1994) Binding and modification of proteins by methylglyoxal under physiological conditions. A kinetic and mechanistic study with N alpha-acetylarginine, N alpha-acetylcysteine, and N alpha-acetyllysine, and bovine serum albumin. J Biol Chem 269: 32299-32305.
34. Lewis GF, Cabana VG, (1996) Postprandial changes in high-density lipoprotein composition and subfraction distribution are not altered in patients with insulin-dependent diabetes mellitus. Metabolism 45: 1034-1041.
35. Nanjee MN, Crouse JR, King JM, Hovorka R, Rees SE, et al. (1996) Effects of intravenous infusion of lipid-free apo A-I in humans. Arterioscler Thromb Vasc Biol 16: 1203-1214.
36. Tubb MR, Silva RA, Pearson KJ, Tso P, Liu M, et al. (2007) Modulation of apolipoprotein A-IV lipid binding by an interaction between the N and C termini. J Biol Chem 282: 28385-28394.
37. Thornalley PJ, (2003) Use of aminoguanidine (Pimagedine) to prevent the formation of advanced glycation endproducts. Arch Biochem Biophys 419: 31-40.
38. Rashid I, van Reyk DM, Davies MJ, (2007) Carnosine and its constituents inhibit glycation of low-density lipoproteins that promotes foam cell formation in vitro. FEBS Lett 581: 1067-1070.
39. Machado AP, Pinto RS, Moyses ZP, Nakandakare ER, Quintao ECR, et al. (2006) Aminoguanidine and metformin prevent the reduced rate of HDL-mediated cell cholesterol efflux induced by formation of advanced glycation end products. Int J Biochem Cell Biol 38: 392-403.
40. Brown BE, Mahroof FM, Cook NL, van Reyk DM, Davies MJ, (2006) Hydrazine compounds inhibit glycation of low-density lipoproteins and prevent the in vitro formation of model foam cells from glycolaldehyde-modified low-density lipoproteins. Diabetologia 49: 775-783.
41. Nangaku M, Miyata T, Sada T, Mizuno M, Inagi R, et al. (2003) Anti-hypertensive agents inhibit in vivo the formation of advanced glycation end products and improve renal damage in a type 2 diabetic nephropathy rat model. J Am Soc Nephrol 14: 1212-1222.
42. Haik GM Jr, Lo TW, Thornalley PJ, (1994) Methylglyoxal concentration and glyoxalase activities in the human lens. Experimental eye research 59: 497-500.